Cwm LLC Reduces Holdings in Zoetis Inc. $ZTS

Cwm LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 61.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,254 shares of the company’s stock after selling 33,786 shares during the period. Cwm LLC’s holdings in Zoetis were worth $2,674,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Zoetis by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after buying an additional 419,777 shares during the period. Nordea Investment Management AB increased its stake in Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after buying an additional 2,179,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after buying an additional 550,859 shares during the period. Alliancebernstein L.P. increased its stake in Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after buying an additional 496,320 shares during the period. Finally, Fundsmith LLP increased its stake in Zoetis by 25.3% during the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock worth $528,966,000 after buying an additional 730,300 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $116.01 on Friday. The company has a 50-day moving average of $121.02 and a 200-day moving average of $125.73. The company has a market capitalization of $48.80 billion, a P/E ratio of 19.27, a PEG ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a 1-year low of $113.29 and a 1-year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Analyst Ratings Changes

Several research firms recently issued reports on ZTS. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.